

Press Release

***Personalised cancer treatments:***

**Biomnis, in partnership with ODPM, is releasing a test to determine the toxicity risk to 5-FU chemotherapy.**

- *5-FU (5-fluorouracil) is included in over 60% of all chemotherapy treatments -*
- *ODPM (Onco Drug Personalized Medicine) has developed a protocol that avoids the severe toxic effects that can be caused by chemotherapy treatments -*
- *In France, these innovative pharmacogenetic tests are exclusively performed by Biomnis laboratories -*

**Lyon, 12 January 2016** - [Biomnis](#), a European leader in specialised medical testing, has announced the launch of a protocol for pharmacogenetic tests following the creation of a cancer treatment partnership with [ODPM](#).

The protocol is based on two complementary approaches to avoiding the severe toxic effects that can be caused by treatments with 5-FU during chemotherapy:

- 5-FU<sup>ODPM Tox™</sup>: a test to detect patients with a high toxicity risk.
- 5-FU<sup>ODPM Protocol™</sup>: a test that can be performed throughout treatment, using a simple blood test, to ensure that the circulating quantity of 5-FU is appropriate for the patient, and enables dose adjustment as required.

**5-FU is a molecule present in over 60% of chemotherapy treatments**

5-Fluorouracil (5-FU), from the Fluoropyrimidine family, is one of the main cancer treatments, used in over 60% of cancers (gastrointestinal, ENT, breast, etc).

However, using these molecules can cause many, occasionally severe, toxic effects. These toxic effects are due to overexposure to the drug linked to inter-individual variations in metabolic rates.

**The right drug, for the right person, at the right dose**

Biomnis and ODPM have created this partnership as part of a common desire to develop personalised treatment in order to provide reliable and innovative tests and improve therapeutic care for patients.

Individual patients will react differently to treatment depending on their sex, age, genetic disposition or lifestyles. If the drug dosage is too low for a patient, their treatment will be ineffective; if it is too high, the toxic effects can be severe and detrimental to the effectiveness of the treatment.

The aim of personalised treatment is to achieve optimum efficiency while eliminating severe side effects.

### **Clinical experience with over 18,000 patients**

Founded in 2010, ODPM develops and markets solutions for personalised cancer treatments. Its services are the result of research work by the Oncopharmacology laboratory of Institute of Cancer Research in Western France (Institut de Cancérologie de l'Ouest - ICO) at their Paul Papin and University of Angers site in Angers, France.

For over 15 years, these two analogous, personalised treatment solutions based on 5-FU have been optimised and validated for over 18,000 patients.

With its strong expertise in oncology, pharmacology and pharmacogenetics, Biomnis will now provide these wide ranging tests as well as treatment advice.

### **About Biomnis**

A European leader in specialised medical testing, Biomnis carries out over 32,000 tests per day from a range of over 2,500 tests available, including specialised tests for which the company has appropriate authorisations. Founded in 1897 by Marcel Mérieux and focused on medical testing for over 100 years, Biomnis remains a leader in the field of specialised medical pathology in France. It has kept its position through continuous technological innovation and investment, particularly in areas such as female biology, oncology and personalised medicine, as well as chromosomal and molecular genetics. [www.biomnis.com/international](http://www.biomnis.com/international)

### **About ODPM**

ODPM helps physicians and biologists prevent severe toxic side effects linked to the administration of fluoropyrimidines and personalise treatments by adapting treatment doses for maximum efficiency.

ODPM provides a range of solutions that support patient therapy before and for the duration of their treatment, ensuring greater safety and effectiveness. [www.odpm.fr](http://www.odpm.fr)

**Press Contact:** Constance Lozet – +33 7 78 41 19 70 – [biomnis@ekno.fr](mailto:biomnis@ekno.fr)